199 related articles for article (PubMed ID: 14703018)
1. Development of new prolactin analogs acting as pure prolactin receptor antagonists.
Goffin V; Bernichtein S; Kayser C; Kelly PA
Pituitary; 2003 Sep; 6(2):89-95. PubMed ID: 14703018
[TBL] [Abstract][Full Text] [Related]
2. Development of pure prolactin receptor antagonists.
Bernichtein S; Kayser C; Dillner K; Moulin S; Kopchick JJ; Martial JA; Norstedt G; Isaksson O; Kelly PA; Goffin V
J Biol Chem; 2003 Sep; 278(38):35988-99. PubMed ID: 12824168
[TBL] [Abstract][Full Text] [Related]
3. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation.
Llovera M; Pichard C; Bernichtein S; Jeay S; Touraine P; Kelly PA; Goffin V
Oncogene; 2000 Sep; 19(41):4695-705. PubMed ID: 11032019
[TBL] [Abstract][Full Text] [Related]
4. Development and potential clinical uses of human prolactin receptor antagonists.
Goffin V; Bernichtein S; Touraine P; Kelly PA
Endocr Rev; 2005 May; 26(3):400-22. PubMed ID: 15814850
[TBL] [Abstract][Full Text] [Related]
5. Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay.
Goffin V; Kinet S; Ferrag F; Binart N; Martial JA; Kelly PA
J Biol Chem; 1996 Jul; 271(28):16573-9. PubMed ID: 8663214
[TBL] [Abstract][Full Text] [Related]
6. Prolactin receptor antagonism in mouse anterior pituitary: effects on cell turnover and prolactin receptor expression.
Ferraris J; Boutillon F; Bernadet M; Seilicovich A; Goffin V; Pisera D
Am J Physiol Endocrinol Metab; 2012 Feb; 302(3):E356-64. PubMed ID: 22094470
[TBL] [Abstract][Full Text] [Related]
7. Use of prolactin receptor antagonist to better understand prolactin regulation of pituitary homeostasis.
Ferraris J; Bernichtein S; Pisera D; Goffin V
Neuroendocrinology; 2013; 98(3):171-9. PubMed ID: 23969780
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
9. Prolactin receptor antagonists.
Walker AM
Curr Opin Investig Drugs; 2005 Apr; 6(4):378-85. PubMed ID: 15898345
[TBL] [Abstract][Full Text] [Related]
10. Structural and thermodynamic bases for the design of pure prolactin receptor antagonists: X-ray structure of Del1-9-G129R-hPRL.
Jomain JB; Tallet E; Broutin I; Hoos S; van Agthoven J; Ducruix A; Kelly PA; Kragelund BB; England P; Goffin V
J Biol Chem; 2007 Nov; 282(45):33118-31. PubMed ID: 17785459
[TBL] [Abstract][Full Text] [Related]
11. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.
Xu C; Langenheim JF; Chen WY
Breast Cancer Res Treat; 2012 Jul; 134(1):157-69. PubMed ID: 22270933
[TBL] [Abstract][Full Text] [Related]
12. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRL-G129R.
Chen NY; Holle L; Li W; Peirce SK; Beck MT; Chen WY
Int J Oncol; 2002 Apr; 20(4):813-8. PubMed ID: 11894130
[TBL] [Abstract][Full Text] [Related]
13. Discovery of the improved antagonistic prolactin variants by library screening.
Liu Y; Gong W; Breinholt J; Nørskov-Lauritsen L; Zhang J; Ma Q; Chen J; Panina S; Guo W; Li T; Zhang J; Kong M; Liu Z; Mao J; Christensen L; Hu S; Wang L
Protein Eng Des Sel; 2011 Nov; 24(11):855-60. PubMed ID: 21954059
[TBL] [Abstract][Full Text] [Related]
14. Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists.
Tan D; Chen KE; Khoo T; Walker AM
Cancer Lett; 2011 Nov; 310(1):101-8. PubMed ID: 21775057
[TBL] [Abstract][Full Text] [Related]
15. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors.
Rouet V; Bogorad RL; Kayser C; Kessal K; Genestie C; Bardier A; Grattan DR; Kelder B; Kopchick JJ; Kelly PA; Goffin V
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15199-204. PubMed ID: 20699217
[TBL] [Abstract][Full Text] [Related]
16. S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist.
Bernichtein S; Kinet S; Jeay S; Llovera M; Madern D; Martial JA; Kelly PA; Goffin V
Endocrinology; 2001 Sep; 142(9):3950-63. PubMed ID: 11517174
[TBL] [Abstract][Full Text] [Related]
17. Should prolactin be reconsidered as a therapeutic target in human breast cancer?
Goffin V; Touraine P; Pichard C; Bernichtein S; Kelly PA
Mol Cell Endocrinol; 1999 May; 151(1-2):79-87. PubMed ID: 10411322
[TBL] [Abstract][Full Text] [Related]
18. Prolactin regulates transcription of the ion uptake Na+/Cl- cotransporter (ncc) gene in zebrafish gill.
Breves JP; Serizier SB; Goffin V; McCormick SD; Karlstrom RO
Mol Cell Endocrinol; 2013 Apr; 369(1-2):98-106. PubMed ID: 23395804
[TBL] [Abstract][Full Text] [Related]
19. The many faces of prolactin in breast cancer.
Chen WY
Adv Exp Med Biol; 2015; 846():61-81. PubMed ID: 25472534
[TBL] [Abstract][Full Text] [Related]
20. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
Langenheim JF; Chen WY
Breast Cancer Res Treat; 2005 Apr; 90(3):281-93. PubMed ID: 15830142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
